Find information on medical topics ... of this great resource continues as the Merck Veterinary Manual in the US and Canada and the MSD Manual outside of North America. Professional edition also ...

Principles of Opioid Use in Non-Cancer Pain. Canadian Medical Association Journal. National Institute on Drug Abuse. NIDA InfoFacts: Prescription and Over-the-Counter Medications. The Merck Manuals ...

The U.S. Food and Drug Administration approved the Keytruda combination in malignant pleural mesothelioma in September. Keytruda, a cancer drug that harnesses a patient's immune system to fight tumors ...

Merck & Co. is putting down $30 million upfront to buy Yale spinout Modifi Biosciences, a deal that includes a preclinical asset designed to take on the tough-to-treat brain cancer glioblastoma (GBM).

Three months after revealing that its respiratory syncytial virus (RSV) preventive antibody clesrovimab had passed muster in a phase 2b/3 trial, Merck is putting numbers to the claim. Clesrovimab ...

Oct 17 (Reuters) - (This Oct. 17 story has been corrected to say that the drug reduced some types of respiratory infection, not all, in the headline and paragraphs 1 and 2) Merck (MRK.N), opens ...

Merck’s MRK stock has declined 14.4% in the past six months against an increase of 9.7% for the Large Cap Pharmaceuticals industry. The stock has also underperformed the sector and the S&P 500 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Despite Merck & Co. homing in on approval for its infant respiratory syncytial virus (RSV) antibody clesrovimab, Sanofi—which last year won its own nod for its AstraZeneca-partnered RSV ...

“We are honored to have Merck recognize the potential of our science, and as an oncology company, they are perfectly positioned to advance our innovations through clinical trials and ...